XNYS · Medical Distribution
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$348.71+0.85%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
54/100
Moderate
Score components
TickerWhale View
Cencora scores 54 out of 100 overall, which we rate moderate. Technical is its strongest area and Risk its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%36Weak
- Revenue growth 5.1%
- EPS growth 38.6%
Valuation
25%76Strong
- P/E 25.8
- EV/Sales 0.2
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
#198 by market cap in our coverage · ~51,000 employees · Listed 1995-04-04 · www.cencora.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#80 / 139sector rank by TickerWhale Score
TickerWhale Score 54 vs sector average 54.6 (-0.6)
Revenue growth (sector)Top 76%
Gross margin (sector)Top 97%
Return on equity (sector)Top 5%
P/E (sector)Cheaper than 70%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
81/100Strong vs universe
Ranks 81st of 100 covered names on our technical composite — the composite itself scores 75/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
6 buy · 0 sell · 2 neutral of 8 votes
TickerWhale rates COR's technical setup strong — 81st percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+10.1%
- vs 50-day+6.9%
Momentum
Constructive
- RSI (14)61 · neutral
- Stochasticbuy
- CCIbuy
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength23· trending
- MACD (12,26,9)buy(histogram 0.735)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 5 buy · 0 sell · 2 neutral.
Result — 6 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)25.8
- P/S (TTM)0.2
- P/B22.2
- EV/EBITDA—
- EV/Sales0.2
- PEG0.67
Profitability & returns
- Gross margin4.0%
- Net margin0.8%
- ROE81.4%
- Debt/Equity3.84
Growth
- Revenue growth (YoY)5.1%
- EPS growth (YoY)38.6%
Green favourable · red stretched — multiples and D/E vs sector peers, margins and growth vs absolute thresholds.
Market capitalisation — $67.6B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Sep '25 | Sep '24 | Sep '23 |
|---|---|---|---|
| Revenue | $321.3B | $294.0B | $262.2B |
| Gross profit | $11.5B | $9.9B | $9.0B |
| Operating income | $2.6B | $2.2B | $2.3B |
| Net income | $1.6B | $1.5B | $1.7B |
| EPS (diluted) | $7.96 | $7.53 | $8.53 |
| Free cash flow | $3.2B | $3.0B | $3.5B |
| Cash | $4.4B | $3.1B | $2.6B |
| Total debt | $7.7B | $4.4B | $4.8B |
| Equity | $1.5B | $646M | $522M |
| Net debt | $3.3B | $1.3B | $2.2B |
| Debt / equity | 5.08 | 6.79 | 9.17 |
| Liabilities / assets | 0.98 | 0.99 | 0.99 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CORCurrentCencora | 54 | 75 | 25.8 | — | 22.2 | 0.2 | $348.71 | +0.85% | +5.1% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.